BIO-TECHNE CORP
Bio-Techne Corporation (TECH) supplies reagents, instruments and services used in life-science research, diagnostics and biopharma development. Investors should know it primarily sells consumables and specialised instruments to research organisations, pharmaceutical companies and clinical labs — a mix that can provide recurring revenue from consumables alongside more cyclical instrument sales. Growth has been driven by new product introductions, recurring demand for assays and reagents, and periodic acquisitions that expand capability and geographic reach. Key risks include sensitivity to research and R&D spending cycles, competitive pressure from other suppliers, supply-chain disruptions and regulatory or reimbursement shifts that can affect diagnostic adoption. The company’s market capitalisation is about $9.88bn, which positions it as a mid‑cap player in the life‑sciences tools space. This summary is educational, not investment advice: values can rise and fall and past performance is not a guarantee of future results. Review the latest financial reports and consider your own circumstances before deciding.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying BIO-TECHNE's stock with a target price of $69.67, indicating potential growth.
Financial Health
BIO-TECHNE CORP is performing well with strong profits and revenue, indicating solid financial health.
Dividend
BIO-TECHNE's low dividend yield of 0.67% suggests limited income for investors seeking dividends. If you invested $1000 you would be paid $6.70 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring TECH
Biotech's IP Moat
This carefully selected group of stocks features biotech companies with powerful patent portfolios. These firms are at the forefront of medical innovation in areas like gene editing and mRNA technology, where intellectual property can create lasting competitive advantages and drive long-term growth.
Published: July 11, 2025
Explore Basket3D-Bioprinted Tissues
These cutting-edge companies are building the future of medicine by printing living human tissues layer by layer. Selected by expert analysts, this collection represents one of healthcare's most promising frontiers with potential to revolutionize transplantation and drug development.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Research tools demand
Rising R&D spending and biotech activity can support steady demand for reagents and assays, though demand can fluctuate with research budgets.
Diversified customer base
Sales to academic, biotech, pharma and clinical labs can smooth revenue, but geographic and customer concentration risks remain.
M&A and innovation
Acquisitions and product launches can accelerate capability and growth, but integration and execution risks should be monitored.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
